FDA: No Approval for Bladder Cancer Drug Vicineum
Vicineum is an investigational locally administered recombinant fusion protein that targets EpCAM antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.
Oncology
COVID-19 Impacts Oncology Clinical Trials
American Society of Clinical Oncology survey shows that the COVID-19 pandemic has created challenges in how oncology clinical trials are conducted, but lessons learned from the experience could lead to more efficiently conducted trials after the pandemic has waned.
Talzenna Dosing Updated to Include Patients With Severe Renal Impairment
The prescribing information for Talzenna (talazoparib; Pfizer) has been updated to include recommendations for patients with severe renal impairment.
Bavencio Plus Inlyta Approved as First-Line Tx for Advanced Renal Cell Carcinoma
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Metastatic PCa Is On the Rise
Between 2007 to 2013, the incidence of metastatic PCa increased by 7.1% annually.
Fewer Early PCa Diagnoses Following USPSTF Recs
Early prostate cancer diagnosis rates fell, while cases of advanced prostate cancer remained stable.
Selenium May Cut Aggressive Prostate Cancer Risk
An analysis of individual participant data from 15 prospective studies suggests a protective effect.
Active Surveillance Possible Before Treatment in mRCC
Some metastatic RCC patients may safely undergo surveillance prior to starting systematic therapy.
Intestinal Autoimmunity Possibly Linked to ADT
ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.
Identity Factors Influence Prostate Cancer Treatment Method
Ethnicity, education identified as factors that influence patients treatment decisions.
- Loading...
Loading...
Loading... 
Loading...